Deciphera Pharmaceuticals, LLC is a commercial-stage biopharmaceutical company headquartered in Waltham, Massachusetts, with research facilities in Lawrence, Kansas. A wholly owned subsidiary of Ono Pharmaceutical Co., Ltd. since 2024, it focuses on discovering, developing, and commercializing kinase inhibitor medicines, primarily for cancer patients.
Leveraging its proprietary switch-control kinase inhibitor platform, Deciphera targets oncology, neurology, and immunology indications with high unmet needs. Key approved products include QINLOCK (ripretinib), a treatment for advanced gastrointestinal stromal tumor (GIST) in patients previously treated with three or more kinase inhibitors, approved in the US and EU; and ROMVIMZA (vimseltinib), for symptomatic tenosynovial giant cell tumor (TGCT) where surgery is not viable, approved in the US and EU.
The company maintains a pipeline of candidates such as tirabrutinib for relapsed/refractory primary central nervous system lymphoma and others addressing GIST, polycythemia vera, and more. Founded in 2003, Deciphera operates commercial platforms in the US and Europe.
Official website: deciphera.com
To provide comprehensive coverage, we aggregate data and news under the name Deciphera, encompassing the following company names, divisions, and related entities:
Deciphera Pharmaceuticals, Inc..
This list encompasses current and former names, alternate names, and key divisions associated with Deciphera, ensuring you can easily find all relevant information under a single, unified profile.
